References
- Amsellem-Ouazana D, Younes P, Conquy S, et al (2005). Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol, 47, 582-6. https://doi.org/10.1016/j.eururo.2005.01.015
- Barash O, Peled N, Tisch U, et al (2012). Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine, 8, 580-9. https://doi.org/10.1016/j.nano.2011.10.001
- Biglarian A, Bakhshi E, Gohari MR, et al (2012). Artificial neural network for prediction of distant metastasis in colorectal cancer. Asian Pac J Cancer Prev, 13, 927-30. https://doi.org/10.7314/APJCP.2012.13.3.927
- Cho WC (2007). Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother, 61, 515-9. https://doi.org/10.1016/j.biopha.2007.08.005
- Chu XY, Hou XB, Song WA, et al (2011). Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis. Cancer Biol Ther, 11, 995-1000. https://doi.org/10.4161/cbt.11.12.15526
- Farlow EC, Vercillo MS, Coon JS, et al (2010). A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer, 103, 1221-8. https://doi.org/10.1038/sj.bjc.6605865
- Feng F, Wu Y, Wu Y, et al (2012). The effect of artificial neural network model combined with six tumor markers in auxiliary diagnosis of lung cancer. J Med Syst, 36, 2973-80. https://doi.org/10.1007/s10916-011-9775-1
- Gaarenstroom KN, Bonfrer JM, Kenter GG, et al (1995). Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer, 76, 807-13. https://doi.org/10.1002/1097-0142(19950901)76:5<807::AID-CNCR2820760515>3.0.CO;2-M
- Gopinath B, Shanthi N (2013). Support Vector Machine based diagnostic system for thyroid cancer using statistical texture features. Asian Pac J Cancer Prev, 14, 97-102. https://doi.org/10.7314/APJCP.2013.14.1.97
- Gwak HK, Lee JH, Park SG (2014). Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer. Asian Pac J Cancer Prev, 15, 4933-8. https://doi.org/10.7314/APJCP.2014.15.12.4933
- Kim YW, Bae SM, Lim H, et al (2012). Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS One, 7, 44960. https://doi.org/10.1371/journal.pone.0044960
- Kligerman S, Abbott G (2010). A radiologic review of the new TNM classification for lung cancer. AJR Am J Roentgenol, 194, 562-73. https://doi.org/10.2214/AJR.09.3354
- Kusy M, Obrzut B, Kluska J (2013). Application of gene expression programming and neural networks to predict adverse events of radical hysterectomy in cervical cancer patients. Med Biol Eng Comput, 51, 1357-65. https://doi.org/10.1007/s11517-013-1108-8
- Lee JG, Cho BC, Bae MK, et al (2009). Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer, 63, 106-10. https://doi.org/10.1016/j.lungcan.2008.04.011
- Lee JH (2013). Clinical Usefulness of Serum CYFRA 21-1 in Patients with Colorectal Cancer. Nucl Med Mol Imaging, 47, 181-7. https://doi.org/10.1007/s13139-013-0218-4
- Leidinger P, Keller A, Heisel S, et al (2010). Identification of lung cancer with high sensitivity and specificity by blood testing. Respir Res, 11, 18. https://doi.org/10.1186/1465-9921-11-18
- Li J, Chen P, Mao CM, et al (2014). Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer. Asia Pac J Clin Oncol, 10, 141-8. https://doi.org/10.1111/ajco.12066
- Li J, Orlandi R, White CN, et al (2005). Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem, 51, 2229-35. https://doi.org/10.1373/clinchem.2005.052878
- Molina R, Filella X, Auge JM, et al (2003). Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol, 24, 209-18. https://doi.org/10.1159/000074432
- Nakata B, Takashima T, Ogawa Y, et al (2004). Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer, 91, 873-8.
- Nevins JR (2011). Pathway-based classification of lung cancer: a strategy to guide therapeutic selection. Proc Am Thorac Soc, 8, 180-2. https://doi.org/10.1513/pats.201006-040MS
- Onitilo AA, Engel JM, Stankowski RV, et al (2012). High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat, 134, 291-8. https://doi.org/10.1007/s10549-012-2039-z
- Ono A, Takahashi T, Mori K, et al (2013). Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer, 13, 354. https://doi.org/10.1186/1471-2407-13-354
- Patz EF, Jr., Campa MJ, Gottlin EB, et al (2007). Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol, 25, 5578-83. https://doi.org/10.1200/JCO.2007.13.5392
- Perkins GL, Slater ED, Sanders GK, et al (2003). Serum tumor markers. Am Fam Physician, 68, 1075-82.
- Raj V, Bajaj A, Entwisle JJ (2011). Implications of new (seventh) TNM classification of lung cancer on general radiologists-a pictorial review. Curr Probl Diagn Radiol, 40, 85-93. https://doi.org/10.1067/j.cpradiol.2010.02.002
- Schneider J, Bitterlich N, Velcovsky HG, et al (2002). Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol, 7, 145-51. https://doi.org/10.1007/s101470200021
- Taguchi F, Solomon B, Gregorc V, et al (2007). Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst, 99, 838-46. https://doi.org/10.1093/jnci/djk195
- Tomita M, Shimizu T, Ayabe T, et al (2010). Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res, 30, 3099-102.
- Travis WD (2011). Classification of lung cancer. Semin Roentgenol, 46, 178-86. https://doi.org/10.1053/j.ro.2011.02.003
- Travis WD, Travis LB, Devesa SS (1995). Lung cancer. Cancer, 75, 191-202. https://doi.org/10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y
- Tureci O, Mack U, Luxemburger U, et al (2006). Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett, 236, 64-71. https://doi.org/10.1016/j.canlet.2005.05.008
- Wang WJ, Tao Z, Gu W, et al (2013). Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination. Asian Pac J Cancer Prev, 14, 4369-71. https://doi.org/10.7314/APJCP.2013.14.7.4369
- Welch HG, Schwartz LM, Woloshin S (2000). Are increasing 5-year survival rates evidence of success against cancer? JAMA, 283, 2975-8. https://doi.org/10.1001/jama.283.22.2975
- Wieskopf B, Demangeat C, Purohit A, et al (1995). Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest, 108, 163-9. https://doi.org/10.1378/chest.108.1.163
- Wrona A, Jassem J (2010). [The new TNM classification in lung cancer]. Pneumonol Alergol Pol, 78, 407-17.
- Yang ZM, Ding XP, Pen L, et al (2014). Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers. Asian Pac J Cancer Prev, 15, 3451-5. https://doi.org/10.7314/APJCP.2014.15.8.3451
- Zhang D, Ren WH, Gao Y, et al (2013). Clinical significance and prognostic value of pentraxin-3 as serologic biomarker for lung cancer. Asian Pac J Cancer Prev, 14, 4215-21. https://doi.org/10.7314/APJCP.2013.14.7.4215
- Zhao D, Xiong Y, Lei QY, et al (2013). LDH-A acetylation: implication in cancer. Oncotarget, 4, 802-3.
- Zhong J, Wang J, Peng W, et al (2013). Prediction of essential proteins based on gene expression programming. BMC Genomics, 14, 7. https://doi.org/10.1186/1471-2164-14-7
- Ziaian B, Saberi A, Ghayyoumi MA, et al (2014). Association of high LDH and low glucose levels in pleural space with HER2 expression in non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1617-20. https://doi.org/10.7314/APJCP.2014.15.4.1617
Cited by
- Combination of Circulating Tumor Cells with Serum Carcinoembryonic Antigen Enhances Clinical Prediction of Non-Small Cell Lung Cancer vol.10, pp.5, 2015, https://doi.org/10.1371/journal.pone.0126276
- Pemetrexed Induces G1 Phase Arrest and Apoptosis through Inhibiting Akt Activation in Human Non Small Lung Cancer Cell Line A549 vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1507
- Recurrent Syncope Associated with Lung Cancer vol.2015, pp.1687-9635, 2015, https://doi.org/10.1155/2015/309784
- Lung cancer prediction from microarray data by gene expression programming vol.10, pp.5, 2016, https://doi.org/10.1049/iet-syb.2015.0082
- Tumour-associated antigens and their anti-cancer applications vol.26, pp.5, 2016, https://doi.org/10.1111/ecc.12446
- Current and Prospective Protein Biomarkers of Lung Cancer vol.9, pp.11, 2017, https://doi.org/10.3390/cancers9110155
- A novel gene selection algorithm for cancer classification using microarray datasets vol.12, pp.1, 2019, https://doi.org/10.1186/s12920-018-0447-6